Abstract
Mesenchymal stem cells (MSCs) represent a potentially attractive product for achieving successful stem-cell-based therapy. Clinical application studies of the MSCs for a variety of diseases such as graft-versus-host disease, liver fibrosis, heart disease, diabetes, osteoarthritis, and spinal cord injury have been proposed worldwide. While clinical applications of MSC-based therapy (MSCT) increasingly gain popularity among clinical practitioners and researchers, concerns have been raised on quality issues of MSCs among all stem cell-based medicinal products (SCMP). Quality issues are associated with donor’s qualification and in vitro cell processing as well as some still unknown biological characteristics of the MSCs, especially in the context of potential tumorigenicity. Quality issues could affect safety and efficacy of the MSCT. To ensure optimal quality assurance for both safety and efficacy of the stem cell-based therapy in clinical trials, processes for SCMP production, quality control tests are necessary at each step. More specifically, donor identity, stem cell tissue origins, purity, safety, potency, and stability, must be strictly controlled during the entire product development cycle.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
ISSCR guidelines for clinical translation of stem cells (2008).
Wong R. Mesenchymal stem cells: angels or demons? J Biomed Biotech. doi:10.1155/2011/459510:1-8.
Miguel MP, Julian SF, Martinez AB, Pascual CY, Aller MA, Arias J, Motiel FA. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med. 2012;12:574–91.
Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D, Broadwater G, Monroy R, Kurtzberg J. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (ProcymalTM) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant. 2011;17(4):534–41.
Rayment EA, Williams DJ. Concise review: mind the gap: challenges in characterizing and quantifying cell- and tissue-based therapies for clinical translation. Stem Cells. 2010;28:996–1004.
EMA guideline on human cell-based medicinal products (2007).
FDA guidance for human somatic cell therapy and gene therapy (1998).
FDA guidance-content and review of CMC information for human somatic cell therapy IND application (2008).
Chinese Pharmacopoeia, Part III, 2010 Version.
European Pharmacopeia-Method 5.2.3-Cell substrates for the production of vaccines for human use.
WHO – Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks (2010).
FDA guidance for industry-characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications (2010).
ICH guidelines-viral safety evaluation of biotechnology products derived from cell lines of human or animal origin-Q5A(R1)-1999.
ICH guidelines-derivation and characterization of cell substrates used for production of biotechnological/biological products-Q5D-1997.
Guidelines for clinical studies and quality control of human somatic cells (in Chinese) (2003).
FDA guidance-potency tests for cellular and gene therapy (2011).
US Pharmacopeia <1046 > Cellular and tissue-based products.
US Pharmacopeia <1043 > Ancillary materials for cell, gene and tissue-engineered products.
Dominici M, et al. Minimum criteria for defining multipotent stem cells-The ISCT position statement. Cytotherapy. 2006;8(4):315–7.
Lazennec G, Jorgensen C. Concise review: adult multipotent stromal cells and cancer: risk or benefit? Stem Cells. 2008;26(6):1387–94.
Herberts CA, Kwa MS, Hermsen HP. Risk factors in the development of stem cell therapy [J]. J Transl Med. 2011;9:29.
FDA guidance for industry-current good tissue practice (CGTP) and additional requirements for manufactures of human cells, tissues, and cellular and tissue-based products (HCT/Ps).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Yuan, BZ. et al. (2013). Considerations of Quality Control Issues for the Mesenchymal Stem Cells-Based Medicinal Products. In: Zhao, R. (eds) Essentials of Mesenchymal Stem Cell Biology and Its Clinical Translation. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6716-4_18
Download citation
DOI: https://doi.org/10.1007/978-94-007-6716-4_18
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-6715-7
Online ISBN: 978-94-007-6716-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)